Black Diamond Therapeutics Inc
NASDAQ:BDTX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Black Diamond Therapeutics Inc
NASDAQ:BDTX
|
US |
|
E
|
Eles Semiconductor Equipment SpA
MIL:ELES
|
IT |
|
Fiserv Inc
NASDAQ:FISV
|
US |
|
Wesfarmers Ltd
ASX:WES
|
AU |
|
Diamondback Energy Inc
NASDAQ:FANG
|
US |
|
Entergy Corp
NYSE:ETR
|
US |
|
U
|
US Century Bank
NASDAQ:USCB
|
US |
|
Monopar Therapeutics Inc
NASDAQ:MNPR
|
US |
|
A
|
Anglo American Platinum Ltd
JSE:AMS
|
ZA |
|
China Petroleum & Chemical Corp
SSE:600028
|
CN |
|
E
|
Emira Property Fund
JSE:EMI
|
ZA |
|
CF Bankshares Inc
NASDAQ:CFBK
|
US |
Wall St Price Targets
BDTX Price Targets Summary
Black Diamond Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for BDTX is 10.05 USD with a low forecast of 7.07 USD and a high forecast of 14.7 USD.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is BDTX's stock price target?
Price Target
10.05
USD
According to Wall Street analysts, the average 1-year price target for BDTX is 10.05 USD with a low forecast of 7.07 USD and a high forecast of 14.7 USD.
What is the Revenue forecast for Black Diamond Therapeutics Inc?
Projected CAGR
32%
The compound annual growth rate for Revenue over the next 8 years is 32%.
What is the Operating Income forecast for Black Diamond Therapeutics Inc?
Projected CAGR
40%
The compound annual growth rate for Operating Income over the next 8 years is 40%.
What is the Net Income forecast for Black Diamond Therapeutics Inc?
Projected CAGR
22%
The compound annual growth rate for Net Income over the next 8 years is 22%.
